OVER THE PAST DECADE, there has been a significant decline in cardiac surgery–
associated mortality, despite an increase in procedural complexity. Although the average …

Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Background Levosimendan is a calcium-sensitizing drug with inotropic and other properties
that may improve outcomes in patients with sepsis. Methods We conducted a double-blind …

Acute heart failure (HF) and in particular, cardiogenic shock are associated with high
morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents …

The field of mitochondrial ion channels has recently seen substantial progress, including the
molecular identification of some of the channels. An integrative approach using genetics …

The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its
specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments …

Levosimendan is an inodilator indicated for the short-term treatment of acutely
decompensated severe chronic heart failure, and in situations where conventional therapy is …

Takotsubo cardiomyopathy (TTS) has become a recognised clinical entity since the
Japanese scientist Sato first described it in 1990. Despite an increasing number of …

Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for
decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence …

Primary graft dysfunction (PGD) remains the leading cause of early mortality post-heart
transplantation. Despite improvements in mechanical circulatory support and critical care …